Bank of New York Mellon Corp Buys 410,351 Shares of BioNTech SE Sponsored ADR $BNTX

Bank of New York Mellon Corp grew its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 58.8% in the second quarter, Holdings Channel reports. The fund owned 1,108,719 shares of the company’s stock after acquiring an additional 410,351 shares during the quarter. Bank of New York Mellon Corp’s holdings in BioNTech were worth $118,045,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in BioNTech by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company’s stock worth $227,000 after acquiring an additional 209 shares during the last quarter. SBI Securities Co. Ltd. boosted its stake in shares of BioNTech by 7.1% during the first quarter. SBI Securities Co. Ltd. now owns 3,673 shares of the company’s stock valued at $334,000 after purchasing an additional 244 shares in the last quarter. LRI Investments LLC boosted its stake in shares of BioNTech by 234.6% during the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after purchasing an additional 312 shares in the last quarter. Banque Cantonale Vaudoise bought a new stake in shares of BioNTech during the first quarter worth about $36,000. Finally, Hantz Financial Services Inc. increased its stake in shares of BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after buying an additional 472 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Down 0.2%

BNTX opened at $103.14 on Friday. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $129.27. The company has a fifty day moving average of $102.60 and a 200-day moving average of $105.04. The stock has a market cap of $23.23 billion, a PE ratio of -64.46 and a beta of 1.54. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same quarter in the previous year, the firm earned $0.81 EPS. BioNTech’s quarterly revenue was up 22.0% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Analyst Upgrades and Downgrades

BNTX has been the topic of several recent research reports. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a research report on Monday, November 3rd. HC Wainwright reaffirmed a “buy” rating and set a $136.00 price target on shares of BioNTech in a research note on Monday, September 8th. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the stock an “overweight” rating in a report on Tuesday, August 5th. JPMorgan Chase & Co. decreased their price objective on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a report on Thursday, October 23rd. Finally, UBS Group lifted their target price on BioNTech from $115.00 to $117.00 and gave the stock a “neutral” rating in a report on Thursday. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.82.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.